Overview

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Status:
Active, not recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

InxMed (Shanghai) Co., Ltd.

Treatments:

Doxorubicin
Liposomal doxorubicin